Oncology “Me-Too” Drugs Compared With Original Drugs in Randomized Clinical Trials
This cross-sectional study compares US Food and Drug Administration–approved anticancer “me-too,” or next-in-class, drugs with randomized clinical trial comparators of first-in-class drugs.
Authors
- Timothée Olivier (ORCID: https://orcid.org/0000-0002-6936-5783)
- Vinay Prasad (ORCID: https://orcid.org/0000-0002-6110-8221)
- Ghulam Rehman Mohyuddin (ORCID: https://orcid.org/0000-0001-6464-783X)
- Calvin Smith (ORCID: https://orcid.org/0009-0005-0061-6459)
Institutions
- United States Food and Drug Administration (US)
- University of Utah (US)
- University Hospital of Geneva (CH)
- Quinnipiac University (US)
Publication Details
- Journal
- JAMA Internal Medicine
- Published
- 2025-07-14
- DOI
- https://doi.org/10.1001/jamainternmed.2025.2892
- Primary Topic
- Statistical Methods in Clinical Trials
- Type
- article
- Field-Weighted Citation Impact
- 0.00